At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Adoptive Cell Therapy Across Cancer Diagnoses
In Brief
A Phase 2 clinical trial evaluating Autologous tumor-infiltrating lymphocytes, Ipilimumab, and 4 other interventions for Cancer. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This study will perform tumor-infiltrating lymphocyte (TIL)-based adoptive T-cell therapy in combination with checkpoint inhibition on cancer patients across all cancer diagnoses.
Study Details
Timeline
Interventions
Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.
One treatment with ipilimumab (3 mg/kg) prior to tumor resection.
4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.
2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks
2 doses (60 mg/kg) prior to TIL infusion
5 doses (25 mg/m2) prior to TIL infusion